EntryPoint Capital LLC Increases Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)

EntryPoint Capital LLC raised its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 35.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 741 shares of the medical instruments supplier’s stock after buying an additional 193 shares during the period. EntryPoint Capital LLC’s holdings in Mesa Laboratories were worth $81,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. CANADA LIFE ASSURANCE Co raised its stake in Mesa Laboratories by 7.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 6,968 shares of the medical instruments supplier’s stock valued at $761,000 after buying an additional 494 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Mesa Laboratories by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 373,397 shares of the medical instruments supplier’s stock worth $40,973,000 after purchasing an additional 3,119 shares in the last quarter. Motley Fool Asset Management LLC increased its stake in shares of Mesa Laboratories by 643.8% in the 1st quarter. Motley Fool Asset Management LLC now owns 64,776 shares of the medical instruments supplier’s stock worth $7,108,000 after purchasing an additional 56,067 shares in the last quarter. Geneva Capital Management LLC increased its stake in shares of Mesa Laboratories by 2.5% in the 1st quarter. Geneva Capital Management LLC now owns 194,330 shares of the medical instruments supplier’s stock worth $21,324,000 after purchasing an additional 4,801 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of Mesa Laboratories by 4.5% in the 1st quarter. BNP Paribas Financial Markets now owns 7,565 shares of the medical instruments supplier’s stock worth $830,000 after purchasing an additional 327 shares in the last quarter. 90.60% of the stock is currently owned by hedge funds and other institutional investors.

Mesa Laboratories Stock Performance

Shares of NASDAQ:MLAB traded down $0.53 during midday trading on Friday, hitting $107.66. The company had a trading volume of 28,607 shares, compared to its average volume of 45,886. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.37 and a quick ratio of 1.86. The company has a market cap of $582.44 million, a price-to-earnings ratio of -2.34 and a beta of 0.86. Mesa Laboratories, Inc. has a 12-month low of $82.86 and a 12-month high of $145.46. The company has a fifty day moving average of $101.16 and a two-hundred day moving average of $102.62.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings results on Wednesday, June 5th. The medical instruments supplier reported $2.25 earnings per share (EPS) for the quarter. Mesa Laboratories had a positive return on equity of 10.10% and a negative net margin of 117.61%. The business had revenue of $58.90 million during the quarter. On average, equities research analysts expect that Mesa Laboratories, Inc. will post 6.91 EPS for the current fiscal year.

Mesa Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 16th. Investors of record on Friday, August 30th will be paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.59%. The ex-dividend date is Friday, August 30th. Mesa Laboratories’s dividend payout ratio (DPR) is presently -1.36%.

Analyst Upgrades and Downgrades

Separately, Evercore ISI reduced their price objective on Mesa Laboratories from $120.00 to $106.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.